Keytruda's indication breadth across 45+ approved uses creates multiple demand vectors that compound as earlier-stage indications gain utilization, while the 2.5% royalty expiration at year-end 2026 will structurally improve margins on the franchise going forward.
the thesis · admitted · the reason above is the thesis, not printed twice
the finding
The later filing explicitly states Keytruda has been approved in over 45 indications in the U.S., including 19 tumor types and 2 tumor-agnostic indications, bearing on the stated indication breadth.
The report says this changed. It does not say whether that is good or bad, so neither do we.
before · MD&A · 2026-03-31 → 2026-06-30
“Keytruda Qlex , which was initially approved by the FDA in September 2025, is approved in the U.S. in solid tumor indications approved for Keytruda .”
→ after
“Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved in over 45 indications in the U.S., including 19 tumor types and 2 tumor-agnostic indications”
the evidence · every sentence checkedfour sentences · whole, uncut
the claims it rests on
“Combined global sales of Keytruda/Keytruda Qlex grew 5% and 8% in the second quarter and first six months of 2026, respectively”
“Demand in the U.S. was driven by higher utilization across earlier-stage indications, including in certain types of triple-negative breast cancer, bladder cancer, head and neck squamous cell carcinoma, and cervical cancer”
“Keytruda is an anti-PD-1 therapy that has been approved in over 45 indications in the U.S., including 19 tumor types and 2 tumor-agnostic indications”
“Under the terms of the more significant of these agreements, Merck pays a royalty of 2.5% on worldwide net sales of Keytruda; this royalty will continue through 2026, terminating thereafter”